Examples of 'palivizumab' in a sentence
Meaning of "palivizumab"
Palivizumab is an adjective used to describe something that is related to or characteristic of the medication palivizumab, which is used to prevent respiratory syncytial virus (RSV) infection
Show more definitions
- A humanized monoclonal antibody used in the prevention of respiratory syncytial virus infections.
How to use "palivizumab" in a sentence
Basic
Advanced
palivizumab
No deaths related to palivizumab administration were cited.
Palivizumab does not interfere with response to vaccines.
No serious adverse events related to palivizumab were reported.
Palivizumab prophylaxis needs to be implemented for this season.
It contains the active substance palivizumab.
Do not mix the palivizumab liquid and lyophilised formulations.
The active substance is palivizumab.
Palivizumab should not be mixed with any medicinal products or diluents.
Studies using lyophilised palivizumab.
Palivizumab and tiotropium bromide are among those most frequently requested.
Studies using liquid palivizumab.
The use of palivizumab is contraindicated in infants with cyanogenic congenital heart disease.
Liquid formulation of palivizumab.
Palivizumab should be given with caution to patients with thrombocytopaenia or any coagulation disorder.
Lyophilised formulation of palivizumab.
See also
Tiotropium bromide and palivizumab were the medications most often requested in this research.
Effectiveness of palivizumab.
Palivizumab should not be given to a child who has had a severe allergic reaction to it.
This reactivity was not associated with adverse events or alteration in palivizumab serum concentrations.
Serum palivizumab levels at the time of challenge were determined using ELISA.
Two clinical studies were conducted to directly compare liquid and lyophilised formulations of palivizumab.
A sealed container comprising the stable aqueous palivizumab formulation of any one of the preceding claims.
Palivizumab for reducing the risk of severe RSV infection in children.
The most serious adverse reactions occurring with palivizumab are anaphylaxis and other acute hypersensitivity reactions.
There is no minimum interval between an inactivated or living vaccine and palivizumab Synagis.
Palivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells.
Mutagenicity and Carcinogenicity Carcinogenicity studies have not been performed with palivizumab.
O Palivizumab Romifidine and its salts.
Reproduction and Teratology Reproduction studies have not been performed with palivizumab.
Control Ab is palivizumab.
However, palivizumab is not always effective.
No enhancement of pathology was observed at sub-effective doses of palivizumab.
Palivizumab does not affect responses to measles, mumps or rubella vaccines.
In one embodiment, the antibody is palivizumab.
Palivizumab has been studied exclusively in high-risk pediatric populations.
Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Palivizumab is administered intramuscularly, preferably in the anterolateral aspect of the thigh.
The following events were reported during post-marketing experience of palivizumab.
Palivizumab solution does not contain a preservative and should be administered within 3 hours of preparation.
During this period, children normally receive 5 consecutive monthly intramuscular doses of palivizumab.
Palivizumab is administered once a month intramuscularly, preferably in the anterolateral aspect of the thigh.
A process for the preparation of a high concentration stable aqueous palivizumab formulation, comprising,.
Palivizumab does not interfere with reverse transcriptase polymerase chain reaction-based assays.
Non-limiting examples of these other active therapeutic agents are ribavirin and / or palivizumab.
Palivizumab ( pvz ) a humanized immunoglobulin monoclonal antibody that inhibits the replication of rsv.
Common adverse reactions occurring with palivizumab are fever, rash and injection site reaction.
Palivizumab solution should stand at room temperature for a minimum of 20 minutes until the solution clarifies.
A unit dosage form comprising the high concentration stable aqueous palivizumab formulation of claim 21.
Palivizumab -- a humanized monoclonal antibody produced by recombinant DNA technology.
Deaths were balanced between the integrated placebo and palivizumab groups and were not drug-related.
